216 related articles for article (PubMed ID: 19424565)
1. Melanoma: molecular pathogenesis and emerging target therapies (Review).
Russo AE; Torrisi E; Bevelacqua Y; Perrotta R; Libra M; McCubrey JA; Spandidos DA; Stivala F; Malaponte G
Int J Oncol; 2009 Jun; 34(6):1481-9. PubMed ID: 19424565
[TBL] [Abstract][Full Text] [Related]
2. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy.
Yajima I; Kumasaka MY; Thang ND; Goto Y; Takeda K; Yamanoshita O; Iida M; Ohgami N; Tamura H; Kawamoto Y; Kato M
Dermatol Res Pract; 2012; 2012():354191. PubMed ID: 22013435
[TBL] [Abstract][Full Text] [Related]
3. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
4. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.
Meier F; Schittek B; Busch S; Garbe C; Smalley K; Satyamoorthy K; Li G; Herlyn M
Front Biosci; 2005 Sep; 10():2986-3001. PubMed ID: 15970553
[TBL] [Abstract][Full Text] [Related]
5. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Favre G
Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
[TBL] [Abstract][Full Text] [Related]
6. Emerging targeted therapies for melanoma treatment (review).
Russo A; Ficili B; Candido S; Pezzino FM; Guarneri C; Biondi A; Travali S; McCubrey JA; Spandidos DA; Libra M
Int J Oncol; 2014 Aug; 45(2):516-24. PubMed ID: 24899250
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
Meier F; Busch S; Lasithiotakis K; Kulms D; Garbe C; Maczey E; Herlyn M; Schittek B
Br J Dermatol; 2007 Jun; 156(6):1204-13. PubMed ID: 17388918
[TBL] [Abstract][Full Text] [Related]
8. The Ashitaba (
Zhang T; Wang Q; Fredimoses M; Gao G; Wang K; Chen H; Wang T; Oi N; Zykova TA; Reddy K; Yao K; Ma W; Chang X; Lee MH; Rathore MG; Bode AM; Ashida H; Lippman SM; Dong Z
Cancer Prev Res (Phila); 2018 Oct; 11(10):607-620. PubMed ID: 29980517
[TBL] [Abstract][Full Text] [Related]
9. Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer.
Pappalardo F; Russo G; Candido S; Pennisi M; Cavalieri S; Motta S; McCubrey JA; Nicoletti F; Libra M
PLoS One; 2016; 11(3):e0152104. PubMed ID: 27015094
[TBL] [Abstract][Full Text] [Related]
10. Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma.
Pejkova S; Dzokic G; Tudzarova-Gjorgova S; Panov S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016 Nov; 37(2-3):89-97. PubMed ID: 27883322
[TBL] [Abstract][Full Text] [Related]
11. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
[TBL] [Abstract][Full Text] [Related]
12. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
13. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling.
Paluncic J; Kovacevic Z; Jansson PJ; Kalinowski D; Merlot AM; Huang ML; Lok HC; Sahni S; Lane DJ; Richardson DR
Biochim Biophys Acta; 2016 Apr; 1863(4):770-84. PubMed ID: 26844774
[TBL] [Abstract][Full Text] [Related]
14. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model.
Michailidou C; Jones M; Walker P; Kamarashev J; Kelly A; Hurlstone AF
Dis Model Mech; 2009; 2(7-8):399-411. PubMed ID: 19470611
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous melanoma: From pathogenesis to therapy (Review).
Leonardi GC; Falzone L; Salemi R; Zanghì A; Spandidos DA; Mccubrey JA; Candido S; Libra M
Int J Oncol; 2018 Apr; 52(4):1071-1080. PubMed ID: 29532857
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Panka DJ; Atkins MB; Mier JW
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
[TBL] [Abstract][Full Text] [Related]
18. Ras, Raf, and MAP kinase in melanoma.
Solus JF; Kraft S
Adv Anat Pathol; 2013 Jul; 20(4):217-26. PubMed ID: 23752084
[TBL] [Abstract][Full Text] [Related]
19. Melanoma Development: Current Knowledge on Melanoma Pathogenesis.
Lugović-Mihić L; Ćesić D; Vuković P; Novak Bilić G; Šitum M; Špoljar S
Acta Dermatovenerol Croat; 2019 Sep; 27(3):163-168. PubMed ID: 31542060
[TBL] [Abstract][Full Text] [Related]
20. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
